K2 Principal Fund’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

K2 Principal Fund’s Portfolio LUMO Stock Details LUMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-15,836	Closed	-$57.2K	–	326
2022 Q4	$57.2K	Sell	15,836 -40,030	-72%	-$262K	0.01%	172
2022 Q3	$494K	Buy	55,866 +43,371	+347%	+$360K	0.06%	148
2022 Q2	$96K	Buy	+12,495	New	+$100K	0.01%	249

Other funds holding LUMO

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

K2 Principal Fund's LUMO Position: Q1 2023 in Review

K2 Principal Fund sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q1 2023, closing a stake of 15,836 shares — an estimated $57.2K sold.

K2 Principal Fund first reported a position in LUMO in Q2 2022 and held it in 3 quarters. The position peaked at $494K in Q3 2022. 36 funds tracked by Wall St. Rank hold LUMO as of Q1 2023.

K2 Principal Fund reported no remaining Lumos Pharma, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
K2 Principal Fund sold 15,836 Lumos Pharma, Inc. Common Stock shares in Q1 2023, an estimated $57.2K.
K2 Principal Fund first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2022 and held it in 3 quarters.
K2 Principal Fund's Lumos Pharma, Inc. Common Stock position peaked at $494K in Q3 2022.
36 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q1 2023.

Based on K2 Principal Fund's 13F filing for Q1 2023, filed 11 May 2023.